1.71
1.72%
-0.03
Cue Biopharma Inc stock is currently priced at $1.71, with a 24-hour trading volume of 116.45K.
It has seen a -1.72% decreased in the last 24 hours and a +4.91% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.74 pivot point. If it approaches the $1.63 support level, significant changes may occur.
Previous Close:
$1.74
Open:
$1.74
24h Volume:
116.45K
Market Cap:
$83.18M
Revenue:
$3.82M
Net Income/Loss:
$-51.89M
P/E Ratio:
-1.3465
EPS:
-1.27
Net Cash Flow:
$-39.52M
1W Performance:
-1.72%
1M Performance:
+4.91%
6M Performance:
-29.34%
1Y Performance:
-57.78%
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
675 West Kendall Street, Cambridge, MA
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-26-23 | Resumed | Oppenheimer | Outperform |
Nov-21-22 | Initiated | Piper Sandler | Overweight |
Jan-13-22 | Initiated | H.C. Wainwright | Buy |
Jan-03-22 | Initiated | Craig Hallum | Buy |
Nov-24-20 | Initiated | Berenberg | Buy |
Apr-09-20 | Initiated | Stifel | Buy |
Jan-28-20 | Initiated | BTIG Research | Buy |
Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
CUE's 2023 Market Dance: Down -41.29% – Time to Invest? - The InvestChronicle
The InvestChronicle
Financial Health Check: Examining Cue Biopharma Inc (CUE)'s Key Ratios – DWinneX - The Dwinnex
The Dwinnex
Pancreatic Cancer Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight - openPR
openPR
Pancreatic Cancer Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine ... - Barchart
Barchart
Cue Biopharma First Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Yahoo Finance
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
GlobeNewswire
Cue Biopharma Inc Stock (CUE) Financials Data
Cue Biopharma Inc (CUE) Revenue 2024
CUE reported a revenue (TTM) of $3.82 million for the quarter ending September 30, 2023, a -59.14% decline year-over-year.
Cue Biopharma Inc (CUE) Net Income 2024
CUE net income (TTM) was -$51.89 million for the quarter ending September 30, 2023, a -10.87% decrease year-over-year.
Cue Biopharma Inc (CUE) Cash Flow 2024
CUE recorded a free cash flow (TTM) of -$39.52 million for the quarter ending September 30, 2023, a +6.15% increase year-over-year.
Cue Biopharma Inc (CUE) Earnings per Share 2024
CUE earnings per share (TTM) was -$1.20 for the quarter ending September 30, 2023, a +12.41% growth year-over-year.
Cue Biopharma Inc Stock (CUE) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER |
Aug 14 '23 |
Buy |
2.86 |
3,000 |
8,580 |
134,578 |
About Cue Biopharma Inc
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers and autoimmune disorders. The company's lead drug candidate includes CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to human papilloma virus related cancers. Its biologics drug candidates also comprise CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. The company also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. Cue Biopharma, Inc. has collaboration agreements with Merck & Co. for the research and development of its proprietary biologics that target autoimmune disease indications; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. It also has a strategic collaboration with LG Chem Life Sciences for Immuno- STATs biologics in oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is based in Cambridge, Massachusetts.
Cap:
|
Volume (24h):